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Comparison of the Clinical Performance of PapilloCheck Human
Papillomavirus Detection with That of the GP5/6-PCR–Enzyme
Immunoassay in Population-Based Cervical Screening
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We compared the clinical performance of the PapilloCheck human papillomavirus (HPV) assay with that of
the GP5/6-PCR method with an enzyme immunoassay readout (GP5/6-PCR–EIA) for the detection
of high-risk HPV (hrHPV) types by the use of cervical samples originating from women in a population-based
by the use of cervical screening cohort tested by combined cytology and GP5/6-PCR–EIA (POBASCAM
trial). Specimens from a random sample of 1,437 controls (women ages 40 to 60 years with normal cytological
findings and without evidence of cervical intraepithelial neoplasia grade 2 or higher [>CIN2] within up to 8
years of follow-up) and 192 cases (women ages 30 to 60 years in whom>CIN3 was detected within up to 3 years
of follow-up) were subjected to analysis by the PapilloCheck method. When all 17 (probably) hrHPV types were
taken into account, the PapilloCheck assay had a clinical sensitivity for the detection of >CIN3 of 96.4%
(185/192 samples; 95% confidence interval [CI], 93.7 to 99.7) and a clinical specificity for the detection of
>CIN2 of 96.3% (95% CI, 95.3 to 97.3). After restriction of the analysis by the PapilloCheck assay to the 14
hrHPV types targeted by GP5/6-PCR–EIA, the clinical sensitivity and clinical specificity values were 95.8%
(95% CI, 92.8 to 98.8) and 96.7% (95% CI, 95.7 to 97.7), respectively. By comparison, these values were 96.4%
(95% CI, 93.9 to 98.9) and 97.7% (95% CI, 96.9 to 98.5), respectively, for the GP5/6-PCR–EIA. When all 17
(probably) hrHPV types were included in the analysis, noninferiority score testing revealed that the clinical
sensitivity of the PapilloCheck assay for the detection of >CIN3 was noninferior to that of the GP5/
6-PCR–EIA (P < 0.0001), but the clinical specificity of the PapilloCheck assay for the detection of >CIN2
was inferior to that of the GP5/6-PCR–EIA (P  0.08) when lower bounds of 90% for sensitivity and 98%
for specificity were used. When the analysis was restricted to the 14 hrHPV types targeted by the GP5/
6-PCR–EIA, both the clinical sensitivity and the clinical specificity of the PapilloCheck assay were nonin-
ferior to those of the GP5/6-PCR–EIA (noninferiority score test; P < 0.0001 and P  0.007, respectively).
Thus, when the findings obtained for the 14 hrHPV types detectable by the GP5/6-PCR–EIA are considered,
the PapilloCheck assay is clinically compatible with the GP5/6-PCR-EIA.
It has been universally accepted that cervical carcinoma and
its closest preinvasive precursor lesion (high-grade cervical in-
traepithelial neoplasia [CIN] lesions) are caused by a persis-
tent infection with one or more of about 14 high-risk human
papillomavirus (hrHPV) types (10, 15). Cervical cancer screen-
ing programs rely on the detection and treatment of cervical
precancerous (high-grade CIN) lesions and treatable cancer in
order to reduce the mortality from this disease. The results of
several large population-based randomized screening trials in-
dicate that compared to cytology, testing for about 14 hrHPV
types results in marked reductions in the incidence of high-
grade CIN lesions and cervical cancers among women who test
negative at follow-up (1, 4, 13, 16–18). This argues for the
implementation of testing for hrHPV in cervical screening
programs at increased intervals.
The tests for hrHPV that were successfully used in these
trials are the commercially available, FDA-approved hrHPV
Hybrid Capture 2 assay (hc2) and the consensus primer GP5/
6-PCR with an enzyme immunoassay (EIA) readout (GP5/
6-PCR–EIA) (1, 4, 13, 16–18). Both assays target hrHPV
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68,
whereas HPV type 66 (HPV-66) is additionally targeted by the
GP5/6-PCR–EIA but is detected by hc2 as a result of
cross-hybridization. Given their better performance character-
istics relative to those of cytology, these tests can be considered
clinically validated for use for cervical screening (14).
It has become clear that different assays for hrHPV display
different clinical sensitivities and clinical specificities for high-
grade CIN lesions and cervical carcinoma (8, 9, 14, 20), and
consequently, hrHPV tests different from hc2 and GP5/
6-PCR–EIA are not necessarily useful for cervical screening
purposes. In order to facilitate the acceptance and suitability of
novel hrHPV assays for cervical screening purposes, guidelines
describing the requirements for the use of HPV tests for pri-
mary screening have recently been provided by a North Amer-
ican-European collaboration (14). These guidelines propose
the use of a clinical validation strategy, based on analysis of the
equivalence of the result of an assay relative to that of a
clinically validated reference HPV test (i.e., hc2), with samples
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that originate from a population-based screening cohort, as
assessed by the use of a noninferiority score test (14). By this
approach, candidate tests for the detection of HPV DNA can
be validated for application in cervical screening programs
without the need to perform large, prospective screening trials.
A relatively novel test for the detection of HPV is the
Greiner Bio-One PapilloCheck assay (7, 11). This assay is a
broad-spectrum PCR-based method that uses a consensus
primer set that targets the E1 region of HPV DNA and that
allows the simultaneous detection and genotyping of 25 differ-
ent HPV types (i.e., 15 hrHPV types (HPV types 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), 2 probably
high-risk HPV genotypes (HPV types 53 and 66), and 8 low-
risk HPV (lrHPV) genotypes (HPV types 6, 11, 40, 42, 43,
44/55, and 70) by DNA chip technology (7, 11). In the study
described here, we assessed the clinical performance of the
PapilloCheck assay relative to that of the GP5/6-PCR–EIA
for the detection of hrHPV in cervical scraping samples col-
lected during the course of the POBASCAM randomized-
controlled cervical screening trial (3–8). In addition, a com-
parative genotyping analysis was performed after genotyping
of the GP5/6-PCR products of GP5/6-PCR–EIA-posi-
tive samples by a reverse line blot (RLB) assay.
MATERIALS AND METHODS
Study population. For this study we used cervical scrapings collected during
the baseline round from women in the intervention group of the population-
based randomized-controlled implementation trial POBASCAM. The women in
this trial were screened by combined cytology and hrHPV GP5/6-PCR–EIA
testing for 14 hrHPV types (5, 6). A detailed description of this trial, including
the referral policy and follow-up procedure, has been published previously (2–4,
6). For this study, samples comprised a representative set of 192 cervical speci-
mens from women (median age, 34 years; age range, 30 to 60 years) who had
histologically confirmed CIN3 lesions or worse (CIN3) detected within a me-
dian follow-up time of 5.3 months (range, 0 to 34.6 months) from the time of
sample collection and detected by either the GP5/6PCR–EIA or cytology, or
both (these are referred to as cases). A random sample of 1,473, cytomorpho-
logically normal cervical scrapings were also obtained from women over 40 years
of age (median age, 49 years; age range, 40 to 60 years) without a high-grade CIN
lesion or worse (CIN lesion grade 2 or higher [CIN2]) within a median fol-
low-up period of 58.7 months (range, 37.2 to 99.5 months) from the time of
sample collection (these are referred to as the controls). Informed consent was
obtained from all study participants, and this study followed the local ethical
guidelines of the medical center.
Specimen collection, GP5/6-PCR–EIA, and RLB assay. In the POBASCAM
trial, cervical samples were subjected to GP5/6-PCR followed by EIA readout
(4, 6). At a later stage, the GP5/6-PCR products of the GP5/6-PCR–
EIA-positive samples were subjected to genotyping by RLB analysis (22). Briefly,
after a conventional cervical smear was made on a glass slide, the remaining
material of the cervical scraping was collected for testing for hrHPV by placing
the brush in 5 ml sterile phosphate-buffered saline (PBS) and 0.05% Merthiolate.
Upon arrival in the laboratory, the samples were spun down and the pellets were
resuspended in 1 ml 10 mM Tris-HCl (pH 8) and stored at80°C for subsequent
analysis for HPV. Aliquots (100 l) were boiled for 10 min and cooled on ice,
and 10 l of the extracts was tested by GP5/6-PCR followed by EIA readout
for 14 hrHPV types (i.e., HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, and 68), as described before (6). The EIA-positive GP5/6-PCR products
were genotyped by the RLB assay, according to previously described protocols
(22). For the purpose of this study, the GP5/6-PCR–EIA and RLB assay
procedures were repeated with DNA extracted from samples that originally
displayed discordant results between the PapilloCheck assay and the GP5/
6-PCR–EIA.
Specimen processing and testing by PapilloCheck assay. Of the selected
cervical scrapings, 1/10th of the original sample was used for DNA extraction
with magnetic beads (Macherey-Nagel, Germany) and an automated DNA ex-
traction platform (Microlab Star; Hamilton Robotics, Switzerland), according to
the recommendations of the manufacturer. The isolated DNA was subjected to
the PapilloCheck assay (Greiner Bio-One, Germany), according to the standard
protocols provided with the kit. Briefly, the PCR amplifies a 350-bp fragment
within the E1 region of the HPV genome by using a broad-spectrum consensus
primer set and simultaneously amplifies a region within the human ADAT1 gene
(adenosine deaminase, tRNA specific 1) as an internal control by using primers
fluorescently labeled with cyanine 5 (Cy5-dUTP) to assess the quality of
the DNA. Furthermore, the performance of the PCR was controlled through the
addition of a control template to the PapilloCheck assay master mixture. The
PCR products were hybridized to HPV type-specific oligonucleotide probes
immobilized on the DNA chip and were detected by the binding of a Cy5-dUTP-
labeled oligonucleotide probe to the tag sequence. The PapilloCheck assay DNA
chip was scanned by the CheckScanner apparatus at wavelengths of 532 nm and
635 nm. Extraction, amplification, hybridization, and orientation controls, as well
as type-specific probes, were spotted on each chip fivefold. A sample was con-
sidered suitable for evaluation in case all controls (five each) were positive and/or
a specimen was positive for at least two spots of any HPV type (i.e., if the
signal-to-noise ratio [SNR] was greater than the automatically defined thresh-
old). The PapilloCheck assay is capable of detecting HPV types 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68, 73, 82, 53, 66, 6, 11, 40, 42, 43, 44/55, and 70. The
test cannot distinguish between HPV-55 and HPV-44 due to cross-reaction.
Statistical analysis. The result of the PapilloCheck assay was initially consid-
ered hrHPV positive when genotyping revealed 1 or more of the 17 (probably)
hrHPV genotypes described by Munoz et al. (15). For further comparative
analysis by the hrHPV GP5/6-PCR–EIA, PapilloCheck assay positivity for
one or more of the 14 hrHPV genotypes detectable by the GP5/6-PCR–EIA
was considered. The clinical sensitivity and clinical specificity values of the
PapilloCheck assay were compared to those of the GP5/6-PCR–EIA by using
a noninferiority score test (14). The thresholds used for noninferiority were
sensitivity for the detection of CIN3 of at least 90% and specificity for the
detection of CIN2 of at least 98% relative to the results of the GP5/6-
PCR–EIA. These lower bounds were the same as those proposed in recent
guidelines that ensure that the negative predictive values are much higher than
those of cytology and, at the same time, that there are a limited number of
false-positive test results, which result in unnecessary follow-up procedures (14).
To investigate the type-specific agreement for the 14 hrHPV types that are
detected by both assays, the typing results were considered to be either concor-
dant (completely identical genotyping results), compatible (both methods de-
tected one or more genotypes in common), or discordant (there was no similarity
between the genotypes detected by the two methods). The two-tailed McNemar
test was used for mutual comparison of the type-specific positivity rates of both
assays. The level of agreement was determined by using the kappa statistic, and
the 2 test was used to compare the distribution of multiple infections between
the assays. Except for noninferiority score testing, SPSS (version 15.0) software
was used for statistical computations. R software was used for noninferiority
score analysis. The level of statistical significance was set at a value of 0.05.
RESULTS
In this study, a series of 1,665 cervical scraping samples
collected at the baseline from women participating in the
POBASCAM trial were subjected to analysis by the PapilloCheck
assay. These included a representative set of 192 scrapings
from women with CIN3 detected at a median follow-up time
of 5.3 months (range, 0 to 34.6 months) from the time of
sample collection and 1,473 samples from women with normal
cytological findings without a diagnosis of CIN2 within a
median follow-up time of 58.7 months (range, 37.2 to 99.5
months) from the time of sample collection. A valid Papillo-
Check test result was obtained for all 192 cases and 1,437 of the
1,473 controls (97.6%; Table 1). The technical specifications of
the samples that gave an invalid PapilloCheck test result were
as follows: for 24 samples, the result for the sample control
(housekeeping gene) was negative; for 2 samples, the result for
the PCR control was negative; and for 10 samples, the results
for both the sample and the PCR controls were negative. Only
the data for samples with a valid PapilloCheck test result were
used for further analysis.
Of the cases, 185 (96.4%) scored PapilloCheck assay positive
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for the 17 (probably) hrHPV types and 2 (1%) scored Papillo-
Check assay positive for lrHPV types, whereas 5 (2.6%)
scored HPV negative (Table 1). Of the controls, the Papillo-
Check assay found that 53 (3.7%) samples were (probably)
hrHPV positive and 22 (1.5%) were lrHPV positive, leaving
1,362 (94.8%) negative samples. Table 2 shows the Papillo-
Check assay results, stratified for cases and controls, in com-
parison to the GP5/6-PCR–EIA findings, both after the
inclusion of all 17 (probably) hrHPV types in the PapilloCheck
test results and after restriction of the analysis to the 14 hrHPV
types (i.e., HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, and 68) that are detectable by the GP5/6-PCR–EIA
(Table 2). Altogether, the PapilloCheck assay had a clinical
sensitivity for the detection of CIN3 of 96.4% (185/192; 95%
confidence interval [CI], 93.7 to 99.7%) and a clinical specific-
ity for the detection of CIN2 of 96.3% (53/1,437; 95% CI,
95.3 to 97.3%) when it was used to detect the 17 (probably)
hrHPV types. After restriction of the PapilloCheck assay anal-
ysis to the 14 hrHPV types targeted by the GP5/6-PCR–
EIA, the clinical sensitivity and the clinical specificity values
were 95.8% (184/192; 95% CI, 92.8 to 98.8%) and 96.7%
(47/1,437; 95% CI, 95.7 to 97.7%), respectively. By compari-
son, these values were 96.4% (185/192; 95% CI, 93.9 to 98.9%)
and 97.7% (33/1437; 95% CI, 96.9 to 98.5%), respectively, for
the GP5/6-PCR–EIA (Table 2). The one case sample that
was PapilloCheck assay positive after analysis for the 17 types
but negative after analysis for the 14 types contained HPV-82.
Four case samples tested positive by the GP5/6-PCR–EIA
but negative by the PapilloCheck assay, whereas three case
samples were positive by the PapilloCheck assay (by analysis
for 14 types) and negative by the GP5/6-PCR–EIA. After
repeat testing by the PapilloCheck assay, three of the four
PapilloCheck assay-negative and GP5/6-PCR–EIA-posi-
tive case samples tested positive for the same genotype(s)
originally found by the GP5/6-PCR–EIA. Of the three
cases missed by the GP5/6-PCR–EIA but positive by the
PapilloCheck assay (by analysis for 14 types), two became
positive with type concordance and one became positive with
type discordance compared to the results of genotyping by the
PapilloCheck assay after repeat testing by GP5/6-PCR–
EIA following DNA extraction. For the control samples, the
PapilloCheck assay analyzing 17 types scored 24 more samples
positive than the GP5/6-PCR–EIA and the PapilloCheck
assay analyzing 14 types scored 18 more samples positive than
the GP5/6-PCR–EIA. The six samples that were addition-
ally detected by the PapilloCheck assay (by analysis of 17
types) were positive for HPV types different from the 14 de-
tected by the GP5/6-PCR–EIA. Of the 18 samples that
were additionally detected by the PapilloCheck assay (by anal-
ysis of 14 types). Original GPS5/6-PCR–EIA values from
the crude extracts were elevated but below the cutoff used.
Twelve of them were subsequently positive by the GP5/6-
PCR–EIA with the isolated DNA and all 12 samples had one
or more HPV types in common with those found by the Pap-
illoCheck assay (data not shown). Of the six remaining discrep-
ant samples, three were positive for HPV-68, one was positive
for HPV-52, one was positive for HPV-56, and one was posi-
tive for HPV-59 by the PapilloCheck assay.
We next performed a noninferiority score test to determine
whether the clinical sensitivity of the PapilloCheck assay for
the detection ofCIN3 and the clinical specificity of the Papillo-
Check assay for the detection of CIN2 were noninferior to
those of the GP5/6-PCR–EIA at thresholds of 90% and
98%, respectively. After the inclusion of all 17 (probably)
hrHPV types in the analysis, the clinical sensitivity of the Papillo-
Check assay was noninferior to that of the GP5/6-PCR–
EIA (P  0.0001), but the specificity was inferior to that of the
GP5/6-PCR–EIA (P  0.08). When the analysis was re-
stricted to the 14 hrHPV types detected by the GP5/6-
PCR–EIA, both the clinical sensitivity and the clinical speci-
TABLE 1. PapilloCheck assay findings for 1,473 cervical scraping
samples collected at the baseline round of the POBASCAM trial
stratified into cases (CIN3) and controls (CIN2 at follow-up)
Group
No. of cervical scraping samples with the following
PapilloCheck assay result:
hrHPVa lrHPVb Negative Notdetermined Total
Cases 185c 2 5 192
Controls 53d 22 1,362 36 1,473
a Positive for 1 or more of the 17 (probable) hrHPV types (i.e., HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82).
b Positive for one or more of the seven lrHPV types (i.e., HPV types 6, 11, 40,
42, 43, 44/55, and 70).
c A total of 184 cervical scraping samples were positive for 1 or more of the 14
hrHPV types also targeted by the GP5/6-PCR–EIA (i.e., HPV types 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).
d A total of 47 cervical scraping samples were positive for 1 or more of the 14
hrHPV types also targeted by GP5/6-PCR–EIA (i.e., HPV types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).
TABLE 2. Comparison of results of PapilloCheck assays for 17 and
14 hrHPV types with GP5/6-PCR–EIA findings stratified for
cases and controls
PapilloCheck assay type,
subject group, and
assay resulta
No. (%) of cervical scraping samples with
the following GP5/6-PCR–EIA resultb:
  Total
PapilloCheck assay positive
for 17 hrHPV types
Controls
 1,380 (96.0) 4 (0.3) 1,384 (96.3)
 24 (1.7) 29 (2.0) 53 (3.8)
Total 1,404 (97.7) 33 (2.3) 1,437
Cases
 3 (1.6) 4 (2.1) 7 (3.6)
 4 (2.1) 181 (94.3) 185 (96.4)
Total 7 (3.6) 185 (96.4) 192
PapilloCheck assay positive
for 14 hrHPV types
Controls
 1,386 (96.5) 4 (0.3) 1,390 (96.7)
 18 (1.3) 29 (2.0) 47 (3.3)
Total 1,404 (97.7) 33 (2.3) 1,437
Cases
 4 (2.1) 4 (2.1) 8 (4.2)
 3 (1.6) 181 (94.3) 184 (95.8)
Total 7 (3.6) 185 (96.4) 192
a The sensitivity and specificity values of the PapilloCheck assay for 17 hrHPV
types for CIN3 were 96.4% and 96.3%, respectively. The sensitivity and spec-
ificity values of the PapilloCheck assay for 14 hrHPV types for CIN3 were
95.8% and 96.7%, respectively.
b The sensitivity and specificity values of the GP5/6-PCR–EIA for CIN3
were 96.4% and 97.7%, respectively.
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ficity of the PapilloCheck assay were noninferior to those of
the GP5/6-PCR–EIA (P  0.0001 and P  0.007, respec-
tively).
At the analytical level, the overall agreement for the detec-
tion of hrHPV (by analysis for 14 types) was 98.2% (1,600/
1,629; 95% CI, 97.6 to 98.8%), with the overall kappa value
being 0.93. The PapilloCheck assay and GP5/6-PCR–EIA
reverse line blot genotyping revealed among the samples that
tested positive concordant genotyping results for 164 (78%)
specimens, compatible results for 41 (20%) specimens, and
discordant genotyping results for only 5 specimens (2%) for 1
or more of the 14 GP5/6-PCR–EIA hrHPV types. The
individual genotyping findings are shown in Table 3. The assays
showed good genotyping agreement (kappa value, 0.60) for
all types except HPV-68, although the number of samples
positive for this HPV type by both assays was low. Even though
the PapilloCheck assay detected significantly more HPV type
31, 51, 52, and 59 infections than the GP5/6-PCR–EIA
(Table 3), these mainly involved samples harboring multiple
hrHPV types (2 test, P  0.02).
DISCUSSION
In the past, the PapilloCheck assay has been compared with
hc2 and the GP5/6-PCR–EIA as well as the Linear Array
assay (Roche Diagnostics) (7, 11), but these comparisons
merely involved the analytical features of the assays. In the
present study, we compared the clinical performance charac-
teristics of the PapilloCheck assay with those of the GP5/6-
PCR–EIA with samples from a cohort of participants originally
screened by both cytology and the GP5/6-PCR–EIA for the
detection of HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, or 68. When the analysis by the PapilloCheck assay was
restricted to the 14 hrHPV types detectable by the GP5/6-
PCR–EIA, both the clinical sensitivity for CIN3 and the
clinical specificity for CIN2 were noninferior to that of the
GP5/6-PCR–EIA by the use of predetermined thresholds
of 90% and 98%, respectively. The inclusion of three addi-
tional (probably) hrHPV types (i.e., HPV types 53, 73, and 82)
resulted in such a decrease in clinical specificity that the Pap-
illoCheck assay became inferior to the GP5/6-PCR–EIA
for this parameter. These findings confirm earlier findings that
the addition of the ability to detect too many types to the test
panel mainly has an adverse impact on the clinical specificity,
whereas the gain in clinical sensitivity is only marginal (12, 14).
In recent guidelines for validation of the use of candidate
HPV assays for screening purposes, the proposed validation
strategy indicates that the candidate test should have a sensi-
tivity for the detection of CIN2 of at least 90% of the sen-
sitivity of hc2, whereas the specificity for the detection of
>CIN2 should be at least 98% of that of hc2 for women at
least 30 years of age (14). In these guidelines, hc2 was chosen
as the reference test since that assay, unlike the GP5/6-
PCR–EIA, is commercially available and therefore widely ap-
plicable. In our study, the reference test was the GP5/6-
PCR–EIA rather than hc2. Like hc2, this assay is clinically
validated for use for screening purposes in large clinical trials,
and its clinical compatibility with hc2 is further supported by its
noninferiority to hc2 in the validation analysis mentioned
above (8, 14). This indicates that this assay is a valid reference
test for use for validation testing as well. Furthermore, since
the GP5/6-PCR–EIA is a PCR-based assay with genotyp-
ing options, similar to the PapilloCheck assay, it allows com-
parative analysis at the genotype level. It is noteworthy, how-
ever, that recent guidelines also include a requirement for
sufficient intralaboratory reproducibility over time and inter-
laboratory agreement, as determined by the evaluation of at
least 500 samples, before a test can be considered suitable for
cervical screening purposes (14).
Overall, there was good genotyping agreement between the
two assays, although the PapilloCheck assay seemed to detect
more HPV type 31, 51, 52, and 59 infections, particularly in
individuals with multiple infections. This good analytical agree-
ment is consistent with the findings of Jones et al. (11), al-
though in that study the detection of HPV-35 appeared to be
an outlier, being found significantly more often by the GP5/
6-PCR–EIA than by the PapilloCheck assay. However, in the
TABLE 3. HPV genotyping results for PapilloCheck assay for 14 hrHPV types versus RLB genotyping data for
PCR products of GP5/6-PCR–EIA-positive samples
HPV
type
No. of samples with the following result:
Kappa
value
McNemar
test value
GP5/6-PCR–EIA
negative/PapilloCheck
assay negative
GP5/6-PCR–EIA
positive/PapilloCheck
assay negative
GP5/6-PCR–EIA
negative/PapilloCheck
assay positive
GP5/6-PCR–EIA
positive/PapilloCheck
assay positive
16 1,486 5 8 130 0.95 0.58
18 1,605 8 3 13 0.70 0.70
31 1,594 2 11 22 0.77 0.02a
33 1,608 2 1 18 0.92 1.00
35 1,623 1 1 4 0.80 1.00
39 1,614 2 5 8 0.70 0.45
45 1,618 4 2 5 0.62 0.69
51 1,609 0 9 11 0.71 0.004a
52 1,607 0 8 14 0.78 0.008a
56 1,617 0 4 8 0.80 0.13
58 1,620 1 1 6 0.86 1.00
59 1,618 0 6 5 0.62 0.03a
66 1,622 2 1 4 0.73 1.00
68 1,621 1 7 0 0.00 0.07
a Statistically significant results.
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study of Jones et al. (11), enzyme immunoassay instead of
reverse line blot analysis was used for the genotyping of the
GP5/6-PCR products. The controls that were additionally
detected by the PapilloCheck assay most likely harbored lower
viral loads in the crude sample extract that originally remained
below the assay detection threshold of the GP5/6-PCR–
EIA. The three discrepant control samples for which the
PapilloCheck assay identified HPV-68 most likely contained an
HPV-68 variant that was less well detected by the primer
combination used in the GP5/6-PCR, as has been de-
scribed by So¨derlund-Strand et al. (21) and Schmitt et al. (19).
Nevertheless, our study indicates that possible minor differ-
ences at the analytical level have no major impact on the
clinical performance characteristics of the two assays.
In conclusion, this study showed that when the 14 hrHPV
types detectable by the GP5/6-PCR–EIA are considered,
the PapilloCheck assay is clinically compatible with the GP5/
6-PCR–EIA for the detection of CIN3.
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